Challenges Encountered in Dermatologic Drug Development
Los desafíos que se encuentran en el desarrollo de fármacos dermatológicos
a Vice President Medical Sciences and Professor and Chairman Emeritus. University of Miami. Department of Dermatology. Stiefel, aGSK Company, Palo Alto, CA. UP Medical Science
b Director, Global Medical Affairs Operations. United States of America
c Chief Scientific Officer. Stiefel, aGSK Company, NC. United States of America
Read
4265
Timeswas read the article
2030
Total PDF
2235
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 126 | 210 | 336 |
| 2025 5 | 67 | 46 | 113 |
| 2025 4 | 54 | 31 | 85 |
| 2025 3 | 50 | 19 | 69 |
| 2025 2 | 42 | 24 | 66 |
| 2025 1 | 25 | 18 | 43 |
| 2024 12 | 16 | 20 | 36 |
| 2024 11 | 27 | 28 | 55 |
| 2024 10 | 21 | 24 | 45 |
| 2024 9 | 18 | 12 | 30 |
| 2024 8 | 24 | 34 | 58 |
| 2024 7 | 24 | 12 | 36 |
| 2024 6 | 34 | 17 | 51 |
| 2024 5 | 18 | 16 | 34 |
| 2024 4 | 17 | 9 | 26 |
| 2024 3 | 17 | 12 | 29 |
| 2024 2 | 12 | 20 | 32 |
| 2024 1 | 9 | 11 | 20 |
| 2023 12 | 11 | 7 | 18 |
| 2023 11 | 12 | 8 | 20 |
| 2023 10 | 13 | 12 | 25 |
| 2023 9 | 10 | 17 | 27 |
| 2023 8 | 13 | 10 | 23 |
| 2023 7 | 7 | 15 | 22 |
| 2023 6 | 5 | 6 | 11 |
| 2023 5 | 9 | 9 | 18 |
| 2023 4 | 5 | 13 | 18 |
| 2023 3 | 13 | 18 | 31 |
| 2023 2 | 12 | 20 | 32 |
| 2023 1 | 17 | 11 | 28 |
| 2022 12 | 14 | 19 | 33 |
| 2022 11 | 14 | 15 | 29 |
| 2022 10 | 8 | 11 | 19 |
| 2022 9 | 7 | 15 | 22 |
| 2022 8 | 9 | 22 | 31 |
| 2022 7 | 7 | 41 | 48 |
| 2022 6 | 7 | 10 | 17 |
| 2022 5 | 11 | 10 | 21 |
| 2022 4 | 25 | 27 | 52 |
| 2022 3 | 33 | 30 | 63 |
| 2022 2 | 14 | 13 | 27 |
| 2022 1 | 8 | 15 | 23 |
| 2021 12 | 9 | 16 | 25 |
| 2021 11 | 17 | 22 | 39 |
| 2021 10 | 20 | 19 | 39 |
| 2021 9 | 8 | 13 | 21 |
| 2021 8 | 17 | 17 | 34 |
| 2021 7 | 10 | 16 | 26 |
| 2021 6 | 9 | 13 | 22 |
| 2021 5 | 10 | 18 | 28 |
| 2021 4 | 26 | 29 | 55 |
| 2021 3 | 22 | 21 | 43 |
| 2021 2 | 17 | 17 | 34 |
| 2021 1 | 11 | 25 | 36 |
| 2020 12 | 11 | 14 | 25 |
| 2020 11 | 13 | 10 | 23 |
| 2020 10 | 4 | 6 | 10 |
| 2020 9 | 7 | 12 | 19 |
| 2020 8 | 13 | 19 | 32 |
| 2020 7 | 7 | 10 | 17 |
| 2020 6 | 13 | 15 | 28 |
| 2020 5 | 8 | 7 | 15 |
| 2020 4 | 16 | 8 | 24 |
| 2020 3 | 16 | 10 | 26 |
| 2020 2 | 1 | 0 | 1 |
| 2019 4 | 2 | 0 | 2 |
| 2019 1 | 1 | 0 | 1 |
| 2018 9 | 1 | 0 | 1 |
| 2018 3 | 1 | 1 | 2 |
| 2018 2 | 16 | 4 | 20 |
| 2018 1 | 14 | 4 | 18 |
| 2017 12 | 10 | 7 | 17 |
| 2017 11 | 12 | 4 | 16 |
| 2017 10 | 9 | 6 | 15 |
| 2017 9 | 5 | 8 | 13 |
| 2017 8 | 8 | 18 | 26 |
| 2017 7 | 9 | 5 | 14 |
| 2017 6 | 16 | 13 | 29 |
| 2017 5 | 10 | 15 | 25 |
| 2017 4 | 12 | 15 | 27 |
| 2017 3 | 13 | 8 | 21 |
| 2017 2 | 9 | 4 | 13 |
| 2017 1 | 8 | 7 | 15 |
| 2016 12 | 8 | 11 | 19 |
| 2016 11 | 13 | 10 | 23 |
| 2016 10 | 28 | 14 | 42 |
| 2016 9 | 15 | 5 | 20 |
| 2016 8 | 11 | 5 | 16 |
| 2016 7 | 12 | 5 | 17 |
| 2016 6 | 0 | 12 | 12 |
| 2016 5 | 0 | 9 | 9 |
| 2016 4 | 0 | 2 | 2 |
| 2016 3 | 0 | 2 | 2 |
| 2016 2 | 0 | 3 | 3 |
| 2016 1 | 2 | 37 | 39 |
| 2015 12 | 0 | 16 | 16 |
| 2015 11 | 6 | 21 | 27 |
| 2015 10 | 2 | 12 | 14 |
| 2015 9 | 3 | 4 | 7 |
| 2015 8 | 3 | 8 | 11 |
| 2015 7 | 21 | 1 | 22 |
| 2015 6 | 14 | 13 | 27 |
| 2015 5 | 34 | 18 | 52 |
| 2015 4 | 37 | 7 | 44 |
| 2015 3 | 33 | 6 | 39 |
| 2015 2 | 12 | 1 | 13 |
| 2015 1 | 11 | 0 | 11 |
| 2014 12 | 23 | 0 | 23 |
| 2014 11 | 17 | 0 | 17 |
| 2014 10 | 16 | 0 | 16 |
| 2014 9 | 31 | 0 | 31 |
| 2014 8 | 19 | 0 | 19 |
| 2014 7 | 19 | 0 | 19 |
| 2014 6 | 29 | 0 | 29 |
| 2014 5 | 34 | 0 | 34 |
| 2014 4 | 30 | 0 | 30 |
| 2014 3 | 37 | 12 | 49 |
| 2014 2 | 29 | 18 | 47 |
| 2014 1 | 25 | 24 | 49 |
| 2013 12 | 44 | 21 | 65 |
| 2013 11 | 26 | 22 | 48 |
| 2013 10 | 23 | 35 | 58 |
| 2013 9 | 20 | 39 | 59 |
| 2013 8 | 20 | 26 | 46 |
| 2013 7 | 30 | 38 | 68 |
| 2013 6 | 24 | 30 | 54 |
| 2013 5 | 25 | 36 | 61 |
| 2013 4 | 22 | 31 | 53 |
| 2013 3 | 21 | 21 | 42 |
| 2013 2 | 22 | 20 | 42 |
| 2013 1 | 11 | 9 | 20 |
| 2012 12 | 6 | 9 | 15 |
| 2012 11 | 7 | 6 | 13 |
| 2012 10 | 7 | 10 | 17 |
| 2012 9 | 3 | 8 | 11 |
| 2012 8 | 1 | 0 | 1 |
| 2010 8 | 2 | 0 | 2 |
| 2010 7 | 5 | 0 | 5 |
| 2010 6 | 5 | 0 | 5 |
| 2010 5 | 3 | 0 | 3 |
| 2010 4 | 8 | 0 | 8 |
Show all
